E84.0
Conditions
Interventions
Group 1: CF Patients with an acute pulmonary exacerbation will be included in the study on the first day (d0) of antibiotic treatment. In-patients and out-patients are recruited in equal parts. The fo
d14, d21). After 4 weeks (d28) all investigations from d0 (see above) will be repeated once again in a final examination.
Sponsors
Klinik für Pädiatrie m. S. Pneumologie und ImmunologieCampus Rudolf Virchow Klinikum
Eligibility
Sex/Gender
All
Age
6 Years to 75 Years
Inclusion criteria
Inclusion criteria: Included in the study are: 1. Patients with CF and acute pulmonary exacerbation (= 2/6 points in clinical symptome score) 2. Patients aged = 6 and = 75 3. Competent patients who have signed the written informed consens 4. Patients able to perform a lung function
Exclusion criteria
Exclusion criteria: Not included in the study are: 1. Patients who have undergone a lung transplantation 2. Patients aged 75 3. Incapacitated patients or patients who have not signed the written informed consens 4. Patients unable to perform a lung function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lung function measurements (specifically: FEV1 measurement) on day 0, day 7, day 14, day 21 and day 28 by using a small FEV1 measurement gauge. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Quality of life using a HRQL-questionnaire, peformed on day 0 and day 28 - Inflammatory markes such as CRP and leukocyten from a blood sample - Duration of antibiotic therapy - BMI on day 0 and day 28 | — |
Countries
Germany
Contacts
Public ContactCarsten Schwarz
Klinik für Pädiatrie m. S. Pneumologie und ImmunologieCampus Rudolf Virchow Klinikum
Outcome results
None listed